Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
ENSEM Therapeutics
company
About
ENSEM Therapeutics is a biotechnology company focusing on high value and difficult-to-drug oncology targets
- 1 - 10
Highlights
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $67M
- Industries
- Biotechnology,Therapeutics
- Founded date
- Jan 1, 2021
- Number Of Employee
- 1 - 10
- Operating Status
- Active
ENSEM Therapeutics is a pioneering drug discovery and development company that leverages its unique Kinetic EnsembleTM platform to develop innovative small-molecule precision medicines for oncology, with potential expansion into genetic disorders and other disease areas.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$67M
ENSEM Therapeutics has raised a total of
$67M
in funding over 2 rounds. Their latest funding was raised on
Apr 6, 2022 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 6, 2022 | Series A | $67M | 2 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
ENSEM Therapeutics is funded by 2 investors.
Cenova Capital
and Pavilion Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series A |
Pavilion Capital
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
